
Olivier Dirat
Senior Director, Global Regulatory Sciences CMC Advisory Office

Olivier Dirat completed his PhD in organic chemistry at Paris University, followed by a post-doctoral position at Stanford University. Olivier has over 25 years of industrial experience in discovery and late-stage API process development at Merck and Pfizer and currently holds the position of Senior Director within Pfizer Global Regulatory Sciences CMC Advisory Office where he provides technical and regulatory guidance and direction to teams on a wide array of topics, including CMC regulatory strategies, the development and articulation of control strategies, impurities management, N-nitrosamines, continuous manufacturing, starting materials, ADCs, peptides, mRNA vaccine lipids and other special cases. He is member of Pfizer’s Impurities Councils, multidisciplinary councils that provides advice to teams regarding impurities (including nitrosamines) from safety, quality and regulatory perspectives. External to Pfizer, Olivier is involved with ICH as rapporteur for ICH Q6(R1) (Specifications), representing PhRMA and was deputy topic lead for ICH Q13 IWG (PhRMA). IQ consortium as Pfizer representative on the Board of Directors, and also on the DSLG and various working groups including Nitrosamines. EFPIA MQEG CMC team and on N-Nitrosamines, ICH M7, and ICH Q6. He has co-authored 45 publications and is a regular conference speaker. Olivier is based in Sandwich, UK.
DAY 1: December 3rd, 2026
SESSION: Nitrosamines – Purge Considerations in Drug Substance Assessments for Nitrosamines
◆ Thematic Focus: General Mutagenic Impurities.
◆ Description: Using the ICH M7 framework to prove that manufacturing processes naturally eliminate impurities justifying the reduction of routine batch testing.
DAY 2: December 5th, 2025
SESSION: Non-mutagenic impurities: Recent advances, regulatory challenges, impact of global divergence and possible solutions via ICH Q6(R1) revision
◆ Overview of recent advances for non-mutagenic impurities.
◆ Potential impact of the EMA reflection paper on non-mutagenic impurities.
◆ Impact of global regulatory divergence and what it means in the real world.
◆ Possible alternative framework for non-mutagenic impurities.
◆ ICH Q6(R1) revision: opportunities for increased harmonisation and use of science and risk-based approaches.
DAY 1: December 4th, 2024
SESSION: Nitrosamine Risk Assessments
◆ Up-versioning the EFPIA DS N-nitrosamine workflow – key changes to be aware of.
◆ A chemistry view of the in-vivo fate of nitrosamines.







